Roche Aktie

Roche für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 891106 / ISIN: US7711951043

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
17.06.2025 03:40:09

Genentech And AbbVie: Venclexta Combo Fails To Extend Survival In Phase III Trial For High-Risk MDS

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for patients with previously untreated higher-risk myelodysplastic syndromes, did not meet its primary endpoint of overall survival at the final analysis.

The companies noted that the safety profile of the Venclexta combination was consistent with the known risk of the individual study medicines and no unexpected safety signals were observed.

According to the companies, the results of the VERONA study have no impact on the approved indications for Venclexta or any ongoing studies.

For More Such Health News, visit rttnews.com.

Analysen zu Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGShmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

AbbVie Inc 161,20 1,38% AbbVie Inc
Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGSh 34,62 2,31% Roche Holding AG Sponsored American Deposit Receipt Repr 1/2 NVTGSh